Profile data is unavailable for this security.
About the company
Nippon Shinyaku Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals and functional foods. The Company has two business segments. The Pharmaceutical Business segment conducts research and development in three focus areas: hematology, intractable and rare diseases (pulmonary arterial hypertension, muscular dystrophy, etc.), and urological and gynecological diseases. The Functional Food Business segment conducts research and development mainly in three categories: health food ingredients, quality-stabilizing preservatives, and protein preparations. Other businesses include business support, non-life insurance agency and life insurance solicitation, real estate rental, and educational support services.
- Revenue in JPY (TTM)160.65bn
- Net income in JPY30.55bn
- Incorporated1919
- Employees2.24k
- LocationNippon Shinyaku Co Ltd14, Nishinosho Monguchi-cho,Kisshoin, Minami-kuKYOTO-SHI 601-8550JapanJPN
- Phone+81 753211111
- Fax+81 753210678
- Websitehttps://www.nippon-shinyaku.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Towa Pharmaceutical Co Ltd | 262.18bn | 16.00bn | 146.67bn | 4.79k | 8.76 | 0.8114 | 4.01 | 0.5594 | 325.11 | 325.11 | 5,325.91 | 3,508.66 | 0.566 | 1.54 | 3.73 | 54,757,100.00 | 3.46 | 3.89 | 4.23 | 5.07 | 36.26 | 37.81 | 6.10 | 6.61 | 1.56 | 734.71 | 0.5794 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Kaken Pharmaceutical Co Ltd | 94.65bn | 12.46bn | 161.90bn | 1.13k | 11.01 | 0.942 | 10.80 | 1.71 | 333.12 | 333.12 | 2,477.35 | 3,894.02 | 0.5391 | 2.04 | 4.10 | 84,056,840.00 | 7.10 | 5.99 | 8.14 | 6.87 | 61.65 | 56.17 | 13.17 | 12.91 | 3.58 | -- | 0.0255 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| Kissei Pharmaceutical Co Ltd | 89.36bn | 12.37bn | 192.22bn | 1.78k | 14.26 | 0.8264 | 11.32 | 2.15 | 289.63 | 289.63 | 2,075.97 | 4,997.78 | 0.3563 | 1.76 | 3.20 | 50,257,030.00 | 4.94 | 4.26 | 5.32 | 4.60 | 49.54 | 48.59 | 13.87 | 14.30 | 4.46 | -- | 0.0061 | 32.41 | 16.87 | 6.91 | 7.18 | 33.54 | 31.04 | 13.97 |
| Sawai Group Holdings Co Ltd | 194.21bn | 2.97bn | 219.14bn | 3.31k | 92.51 | 1.25 | 11.77 | 1.13 | 20.51 | 7.05 | 1,612.14 | 1,521.63 | 0.5378 | 1.25 | 3.64 | 58,672,810.00 | 0.823 | -0.2327 | 1.07 | -0.3187 | 29.75 | 32.95 | 1.53 | -0.475 | 0.8581 | 5.40 | 0.3751 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Nippon Shinyaku Co Ltd | 160.65bn | 30.55bn | 228.04bn | 2.24k | 7.16 | 0.8696 | 6.22 | 1.42 | 453.52 | 453.52 | 2,384.95 | 3,732.95 | 0.5784 | 1.23 | 3.54 | 71,621,490.00 | 11.00 | 10.89 | 12.47 | 12.74 | 68.17 | 63.93 | 19.02 | 17.67 | 3.50 | -- | 0.0095 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| Tsumura & Co | 180.50bn | 25.62bn | 268.35bn | 4.27k | 10.34 | 0.9037 | 6.90 | 1.49 | 338.03 | 338.03 | 2,384.03 | 3,868.60 | 0.3964 | 0.7064 | 2.60 | 42,251,170.00 | 6.05 | 5.53 | 7.76 | 6.85 | 48.90 | 49.39 | 15.27 | 14.50 | 2.35 | 20.02 | 0.2277 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Hisamitsu Pharmaceutical Co Inc | 155.49bn | 19.68bn | 309.83bn | 2.80k | 15.26 | 1.10 | 11.49 | 1.99 | 270.13 | 270.13 | 2,134.73 | 3,739.02 | 0.453 | 2.61 | 3.10 | 55,553,060.00 | 5.86 | 4.34 | 7.03 | 4.99 | 59.73 | 57.83 | 12.95 | 10.32 | 3.38 | -- | 0.0088 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
Data as of Oct 17 2025. Currency figures normalised to Nippon Shinyaku Co Ltd's reporting currency: Japanese Yen JPY
16.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 31 Mar 2025 | 3.28m | 4.67% |
| The Vanguard Group, Inc.as of 03 Sep 2025 | 1.78m | 2.53% |
| Arcus Investment Ltd.as of 30 Sep 2024 | 1.11m | 1.57% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.07m | 1.53% |
| Amova Asset Management Co., Ltd.as of 04 Sep 2025 | 818.70k | 1.17% |
| Daiwa Asset Management Co. Ltd.as of 29 Aug 2025 | 772.20k | 1.10% |
| BlackRock Fund Advisorsas of 04 Sep 2025 | 717.60k | 1.02% |
| Dimensional Fund Advisors LPas of 04 Sep 2025 | 658.68k | 0.94% |
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 04 Sep 2025 | 572.20k | 0.81% |
| Asset Management One Co., Ltd.as of 04 Sep 2025 | 480.30k | 0.68% |
More ▼
Data from 30 Jun 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
